Yorba Linda, California Clinical Trials

A listing of Yorba Linda, California clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 39 clinical trials
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.

body mass index
tirzepatide
cardiovascular disease
dulaglutide
Diabetes Associates Medical Group
 (7.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +650 other locations
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

antihemophilic factor
factor ix
haemophilia a
bethesda assay
hemophilia
Investigational Site Number 8400010
 (7.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +10 other locations
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B With or Without Inhibitory Antibodies to Factor VIII or IX

Primary Objective: To characterize the long-term safety and tolerability of fitusiran Secondary Objectives: To characterize the long-term efficacy of fitusiran as assessed by the frequency of: Bleeding episodes Spontaneous bleeding episodes Target joint bleeding episodes To characterize the effects of fitusiran on health-related quality of life (HRQOL) measures in participants …

antihemophilic factor
haemophilia a
hemophilia
hemarthrosis
fitusiran
Investigational Site Number 8400016
 (7.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +43 other locations
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

antihemophilic factor
factor ix
haemophilia a
bethesda assay
hemophilia
Investigational Site Number 8400010
 (7.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +10 other locations
A Study to Evaluate the Efficacy and Safety of Frexalimab, SAR442970, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease (RESULT)

This is a parallel, Phase 2a, double-blind, 6-arm study for the treatment of primary focal segmental glomerulosclerosis (FSGS) or primary minimal change disease (MCD).The purpose of this study is to measure the change in proteinuria and its impact on the rates of remission of nephrotic syndrome with frexalimab, SAR442970, or …

Investigational Site Number : 8400015
 (7.9 away) Contact site
  • 0 views
  • 20 Jun, 2025
  • +24 other locations
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT …

soft tissue disease
atezolizumab
medical castration
hormonal therapy
prostate adenocarcinoma
Exelixis Clinical Site #2
 (6.8 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +1 other locations
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of AB928-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

prostatic neoplasm
measurable disease
prostatic neoplasms, castration-resistant
combined modality therapy
docetaxel
The University of California, Irvine Medical Center
 (7.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +21 other locations
A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects

This is a randomized, single-blind, placebo-controlled, once daily (QD) dose study of CRV431 in presumed NASH F2/F3 subjects.

fibroscan
fatty liver
vcte
hepatic fibrosis
fibrosis
Conquest Clinical Research
 (7.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +9 other locations
Patient-Derived Xenografts to Reduce Cancer Health Disparities

This trial establishes patient-derived cancer xenografts in addressing cancer health and treatment disparities that disproportionately affect racial/ethnic minorities. Understanding the genetic and response differences among racial/ethnic minorities may help researchers enhance the precision of therapeutic treatments.

lung cancer
liver cancer
cancer
biospecimen collection
bladder cancer
UC Irvine Health/Chao Family Comprehensive Cancer Center
 (7.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +1 other locations